Key points about GSK3915393 in Phase 1: Target me
Post# of 149927
(Total Views: 500)
Posted On: 02/03/2025 3:09:14 AM
Quote:
Key points about GSK3915393 in Phase 1:
Target mechanism:
This drug works by targeting transglutaminase-2 (TG2).
The transglutaminase-2 enzyme that it targets needs high levels of intracellular CA-2+ to activate. Leronlimab downregulates that CA-2+.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼